
X
Immunomedics wows ESMO with breast cancer data reveal
https://pharmaphorum.com/news/immunomedics-wows-esmo-with-breast-cancer-data-reveal/
Clovis’ Rubraca, the drug showing significant benefits for all ovarian cancer patients in a maintenance setting – and better results than its rivals.